RADX ▲ +1.0% - Radiopharm Theranostics Limited $RADX - Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting Radiopharm Theranostics rose 1.0% today following news that it has been selected to present late-breaking interim data from its U.S. Phase 2b imaging trial of RAD101 at the 2026 Society of Neuro-Oncology Annual Meeting. The selection for an oral presentation slot at a major medical conference typically signals positive trial results and suggests the company's lead candidate is progressing toward potential regulatory approval in neuro-oncology. 14-SEP-2026 08:00 AM ET